Market capitalization | JPY6.63t |
Enterprise Value | JPY10.82t |
P/E (TTM) P/E ratio | 22.69 |
EV/FCF (TTM) EV/FCF | 17.65 |
EV/Sales (TTM) EV/Sales | 2.38 |
P/S ratio (TTM) P/S ratio | 1.46 |
P/B ratio (TTM) P/B ratio | 0.96 |
Dividend yield | 4.69% |
Last dividend (FY25) | JPY196.00 |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
15 Analysts have issued a Takeda Pharmaceutical forecast:
15 Analysts have issued a Takeda Pharmaceutical forecast:
Sep '24 |
+/-
%
|
||
Revenue | 4,546,083 4,546,083 |
9%
9%
|
|
Gross Profit | 2,429,981 2,429,981 |
10%
10%
|
|
EBITDA | 1,368,918 1,368,918 |
9%
9%
|
EBIT (Operating Income) EBIT | 610,441 610,441 |
21%
21%
|
Net Profit | 289,996 289,996 |
51%
51%
|
In millions JPY.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Head office | Japan |
CEO | Christophe Weber |
Employees | 49,281 |
Founded | 1781 |
Website | www.takeda.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.